PF-Atlas › Clinical Trials › NCT06016088
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
RSP-1502 · Phase 1
Registry ID
NCT06016088
Phase
Phase 1
Status
Completed
Drug / intervention
RSP-1502
Sponsor
Respirion Pharmaceuticals Pty Ltd
Start
2024-04-01
Enrollment
71
Locations
22
About this trial
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06016088 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.